Ability of Procalcitonin to Discriminate Infection from Non-Infective Inflammation Using Two Pleural Disease Settings

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  McCann, Fiona J ^a   Chapman, Stephen J ^a   Yu, Wai Cho ^c   Maskell, Nick A ^d   Davies, Robert J O ^a   Lee, Y C Gary ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PRINCESS MARGARET HOSPITAL   (Hong Kong)

^d SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; PROCALCITONIN;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; COMPARATIVE STUDY; CONCEPT ANALYSIS; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PLEURA DISEASE; PLEURA EFFUSION; PLEURODESIS; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; RESPIRATORY TRACT INFECTION; SURGICAL TECHNIQUE; SURVIVAL;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CALCITONIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; INFECTION; INFLAMMATION; MALE; MIDDLE AGED; PLEURA; PLEURAL DISEASES; PROTEIN PRECURSORS;

EID: 84871222201     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0049894     Document Type: Article

References (32)

1. Schuetz P, Amin DN, Greenwald JL, (2012) Role of procalcitonin in managing adult patients with respiratory tract infections. Chest 141: 1063-73.
2. Becker KL, Snider R, Nylen ES, (2008) Procalcitonin assay in systemic inflammation, infection, and sepsis: clinical utility and limitations. Crit Care Med 36: 941-52.
3. Russwurm S, Wiederhold M, Oberhoffer M, Stonans I, Zipfel PF, et al. (1999) Molecular aspects and natural source of procalcitonin. Clin Chem Lab Med 37: 789-97.
4. Olah A, Belágyi T, Issekutz A, Makay R, Zaborszky A, (2005) Value of procalcitonin quick test in the differentiation between sterile and infected forms of acute pancreatitis. Hepatogastroenterology 52: 243-5.
5. Brunkhorst FM, Eberhard OK, Brunkhorst R, (1999) Discrimination of infectious and noninfectious causes of early acute respiratory distress syndrome by procalcitonin. Crit Care Med 27: 2172-6.
6. Reinhart K, Meisner M, (2011) Biomarkers in the critically ill patient: procalcitonin. Crit Care Clin 27: 253-63.
7. Tang BM, Eslick GD, Craig JC, McLean AS, (2007) Accuracy of procalcitonin for sepsis diagnosis in critically ill patients: systematic review and meta-analysis. Lancet Infect Dis 7: 210-7.
8. Müller F, Christ-Crain M, Bregenzer T, Krause M, Zimmerli W, et al. (2010) ProHOSP Study Group Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: a prospective cohort trial. Chest 1381: 121-9.
9. Cuquemelle E, Soulis F, Villers D, Roche-Campo F, Ara Somohano C, et al. (2011) Can procalcitonin help identify associated bacterial infection in patients with severe influenza pneumonia? A multicentre study. Intensive Care Med 375: 796-800.
10. Davies HE, Lee YCG (2008) Pleural Effusion, Empyema and Pneumothorax. In: Albert RK, Spiro SG, Jett JR, eds. Clinical Pulmonary Medicine. Philadelphia, PA, USA: Elsevier.853-67.
11. Tobin C, Lee YCG, (2012) Pleural infection- what we need to know but don't. Curr Opin Pulm Med 18: 321-5.
12. West SD, Davies RJO, Lee YCG, (2004) Pleurodeses for malignant pleural effusions: current controversies and variations in practices. Curr Opin Pulm Med 10: 305-10.
13. Lee YCG, Light RW, (2004) Management of malignant pleural effusions. Respirology 9: 148-56.
14. Maskell NA, Davies CW, Nunn AJ, Hedley EL, Gleeson FV, et al. (2005) U.K. Controlled trial of intrapleural streptokinase for pleural infection. N Engl J Med 352: 865-74.
15. Maskell NA, Lee YCG, Gleeson FV, Hedley EL, Pengelly G, et al. (2004) Prospective randomized trials comparing the influence of talc of different particle sizes and tetracycline on lung and systemic inflammation after pleurodesis. Am J Respir Crit Care Med 170: 377-82.
16. Rahman NM, Maskell NA, West A, Teoh R, Arnold A, et al. (2011) The primary result of the Second UK Multi-Centre Intrapleural Sepsis Trial (MIST2): A randomised controlled trial of adjuvant intra-pleural recombinant tissue plasminogen activator and recombinant deoxyribonucleic acidase in pleural infection. New Engl J Med 365: 518-26.
17. Maskell NA, Gleeson FV, Darby M, Davies RJO, (2004) Diagnostically significant variations in pleural fluid pH in loculated parapneumonic effusions. Chest 126: 2022-4.
18. Uzzan B, Cohen R, Nicolas P, Cucherat M, Perret GY, (2006) Procalcitonin as a diagnostic test for sepsis in critically ill adults and after surgery or trauma: a systematic review and meta-analysis. Crit Care Med 34: 1996-2003.
19. Jereb M, Muzlovic I, Hojker S, Strle F, (2001) Predictive value of serum and cerebrospinal fluid procalcitonin levels for the diagnosis of bacterial meningitis. Infection 29: 209-12.
20. Papassotiriou I, Alexiou VG, Tsironi M, Skenderi K, Spanos A, et al. (2008) Severe aseptic inflammation caused by long distance running (246 km) does not increase procalcitonin. Eur J Clin Invest 38: 276-9.
21. Müller B, Peri G, Doni A, Perruchoud AP, Landmann R, et al. (2002) High circulating levels of the IL-1 type II decoy receptor in critically ill patients with sepsis: association of high decoy receptor levels with glucocorticoid administration. J Leukoc Biol 72: 643-9.
22. de Kruif MD, Lemaire LC, Giebelen IA, Groot AP, Pater JM, et al. (2008) The influence of corticosteroids on the release of novel biomarkers in human endotoxemia. Intensive Care Med 343: 518-22.
23. Sahn SA, Heffner JE (2008) Pleural fluid analysis. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases. London, U.K.: Arnold Press.209-26.
24. Rahman NM, Davies RJO (2008) Parapneumonic effusion and empyema. In: Light RW, Lee YCG, eds. Textbook of Pleural Diseases, 2nd ed. London, U.K.: Arnold Press.341-66.
25. Hooper C, Lee YCG, Maskell NA, (2010) on behalf of the British Thoracic Society Pleural Disease Group (2010) The British Thoracic Society Guidelines for the investigation of a unilateral pleural effusion in adults. Thorax 65: ii4-ii17.
26. Brims FJ, Lansley SM, Waterer GW, Lee YCG, (2010) Empyema Thoracic - new insights into an old disease. Eur Respir Rev 19: 220-8.
27. Lin MC, Chen YC, Wu JT, Ko YC, Wang CC, (2009) Diagnostic and prognostic value of pleural fluid procalcitonin in parapneumonic pleural effusions. Chest 136: 205-11.
28. Ko YC, Wu WP, Hsu CS, Dai MP, Ou CC, et al. (2009) Serum and pleural fluid procalcitonin in predicting bacterial infection in patients with parapneumonic effusion. J Koream Med Sci 24: 398-402.
29. Porcel JM, Vives M, Cao G, Bielsa S, Ruiz-Gonzalez A, et al. (2009) Biomarkers of infection for the differential diagnosis of pleural effusions. Eur Respir J in press.
30. Wang CY, Hsiao YC, Jerng JS, Ho CC, Lai CC, et al. (2011) Diagnostic value of procalcitonin in pleural effusions. Eur J Clin Microbiol Infect Dis 30: 313-8.
31. San José ME, Valdés L, Vizcaíno LH, Mora T, Pose A, et al. (2010) Procalcitonin, C-reactive protein, and cell counts in the diagnosis of parapneumonic pleural effusions. J Investig Med 58: 971-6.
32. Agarwal R, Schwartz DN, (2011) Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis 53: 379-87.